The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global non-invasive prenatal testing market exhibited strong growth during 2015-2020. Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman’s blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother’s blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.
The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus. Looking forward, IMARC Group expects the global non-invasive prenatal testing market to grow at a CAGR of 10.70% during 2021-2026.
Breakup by Product Type:
Breakup by Test Type:
Breakup by Technology:
Breakup by Test Type:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the top non invasive prenatal testing companies key players being Agilent Technologies Inc., Berry Genetics Inc., BGI Genomics Co. Ltd., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche AG, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., Perkinelmer Inc., Thermo Fisher Scientific Inc., Yourgene Health, etc.
Key Questions Answered in This Report:
We expect the global non-invasive prenatal testing market to exhibit a CAGR of 10.70% during 2021-2026.
The high prevalence of genetic disorders in the fetus, along with the rising health awareness towards early disease detection at a primitive stage, is one of the key factors driving the global non-invasive prenatal testing market.
The sudden outbreak of the COVID-19 pandemic had hampered the market growth due to the high risk of coronavirus contraction upon hospital visits for numerous medical procedures involved in the prenatal testing.
Based on the test type, the global non-invasive prenatal testing market can be bifurcated into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests, fetal cells in maternal blood tests, and others. Among these, ultrasound detection currently exhibits a clear dominance in the market share.
Based on the application, the global non-invasive prenatal testing market has been divided into trisomy, microdeletions syndrome, and others. Currently, trisomy holds the largest segment.
Based on the end-user, the global non-invasive prenatal testing market can be segmented into hospitals, diagnostic laboratories, and others. Among these, diagnostic laboratories account for the highest market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Currently, North America dominates the global market.
Some of the major players in the global non-invasive prenatal testing market include Agilent Technologies Inc., Berry Genetics Inc., BGI Genomics Co. Ltd., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche AG, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., Perkinelmer Inc., Thermo Fisher Scientific Inc., Yourgene Health, etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at